Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,900 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 4 November 2021) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

 (PDF, 4MB, 246 pages) 

This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website

 

 

Export 6 results:
Author Title [ Type(Desc)] Year
Filters: Author is Appenteng, K.  [Clear All Filters]
Journal Article
V. Hoffman, Hallas, J., Linder, M., Margulis, A. V., Suehs, B. T., Arana, A., Phiri, K., Enger, C., Horter, L., Odsbu, I., Olesen, M., Perez-Gutthann, S., Xu, Y., Kristiansen, N. S., Appenteng, K., de Vogel, S., and Seeger, J. D., Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study, Drug Saf, vol. 44, pp. 899-915, 2021.
E. M. Heintjes, Bezemer, I. D., Prieto-Alhambra, D., Smits, E., Booth, H. P., Dedman, D., He, Y., Hoti, F., Vehkala, M., de Vogel, S., Robinson, N. J., Appenteng, K., and van Beest, F. J. A. Penn, Evaluating the Effectiveness of an Additional Risk Minimization Measure to Reduce the Risk of Prescribing Mirabegron to Patients with Severe Uncontrolled Hypertension in Four European Countries, Clin Epidemiol, vol. 12, pp. 423-433, 2020.
A. V. Margulis, Linder, M., Arana, A., Pottegard, A., Berglind, I. A., Bui, C. L., Kristiansen, N. S., Bahmanyar, S., McQuay, L. J., Atsma, W. J., Appenteng, K., D'Silva, M., Perez-Gutthann, S., and Hallas, J., Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom, PLoS One, vol. 13, p. e0204456, 2018.
K. Phiri, Hallas, J., Linder, M., Margulis, A., Suehs, B., Arana, A., Bahmanyar, S., Hoffman, V., Enger, C., Horter, L., Odsbu, I., Olesen, M., Perez-Gutthann, S., Kristiansen, N. S., Appenteng, K., de Vogel, S., and Seeger, J., A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder, Curr Med Res Opin, p. 1, 2021.
A. Arana, Margulis, A. V., Varas-Lorenzo, C., Bui, C. L., Gilsenan, A., McQuay, L. J., Reynolds, M., Rebordosa, C., Franks, B., de Vogel, S., Appenteng, K., and Perez-Gutthann, S., Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom, Pharmacoepidemiol Drug Saf, 2020.
A. Arana, Margulis, A. V., McQuay, L. J., Ziemiecki, R., Bartsch, J. L., Rothman, K. J., Franks, B., D'Silva, M., Appenteng, K., Varas-Lorenzo, C., and Perez-Gutthann, S., Variation in Cardiovascular Risk Related to Individual Antimuscarinic Drugs Used to Treat Overactive Bladder: A UK Cohort Study, Pharmacotherapy, vol. 38, pp. 628-637, 2018.
[Page last reviewed 4 November 2021]